GRI Bio
About: GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
Employees: 4
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
1.59% less ownership
Funds ownership: 2.51% [Q4 2024] → 0.92% (-1.59%) [Q1 2025]
38% less funds holding
Funds holding: 8 [Q4 2024] → 5 (-3) [Q1 2025]
92% less capital invested
Capital invested by funds: $185K [Q4 2024] → $15.5K (-$170K) [Q1 2025]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 5
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$10
669%
upside
Avg. target
$22
1,592%
upside
High target
$34
2,515%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis | 669%upside $10 | Buy Reiterated | 11 Jun 2025 |
Ascendiant Capital Edward Woo | 2,515%upside $34 | Buy Maintained | 27 May 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
3 weeks ago
GRI Bio to Participate in the Virtual Investor Closing Bell Series
Live webcast on Wednesday, May 28 th at 4:00 PM ET LA JOLLA, CA, May 21, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio will participate in the Virtual Investor Closing Bell Series on Wednesday, May 28, 2025 at 4:00 PM ET. As part of the event, Dr. Hertz will provide a corporate overview and business outlook.
Neutral
GlobeNewsWire
4 weeks ago
GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase
Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer on Wednesday, May 21 st at 2:40 PM ET
Neutral
GlobeNewsWire
1 month ago
GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025
Positive interim 2-week safety and biomarker results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
Neutral
GlobeNewsWire
1 month ago
GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
The Independent Data Monitoring Committee (IDMC) has recommended to continue the study as planned as there are no safety concerns seen in the data reviewed
Neutral
GlobeNewsWire
1 month ago
GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
Enrollment completed for the 6-week interim analysis with 24 of the 36 planned patients now enrolled Company on track to report interim biomarker data from the first 12 patients imminently Completion of patient enrollment and topline results expected Q3 2025 LA JOLLA, CA, May 07, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that enrollment for the 6 week interim analysis is complete with 24 of the 36 planned patients randomized in its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”). “We are pleased with the progress made in this Phase 2a biomarker study.
Neutral
GlobeNewsWire
1 month ago
GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference
LA JOLLA, CA, April 16, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstract has been selected for poster presentation in a poster discussion session at the 2025 ATS International Conference being held May 18-21, 2025 in San Francisco, CA. Details of the presentation are as follows: Title: Inactivation of iNKT Cells After the Inflammatory Phase Leads to Significant Inhibition of Fibroblast Activation and Fibrosis in a Model of Pulmonary Fibrosis Poster Board Number: 810 Presenter: Marc Hertz, PhD, Chief Executive Officer of GRI Bio Session: D21 - IMMUNOLOGICAL INSIGHTS IN LUNG INFLAMMATION AND REPAIR Date and Time: Wednesday, May 21, 2025 from 8:15-10:15 AM PT Location: Room 2022/2024 (West Building, Level 2), Moscone Center For more information about the 2025 ATS International Conference, please visit the conference website, here.
Neutral
GlobeNewsWire
2 months ago
GRI Bio Announces Closing of $5.0 Million Public Offering
LA JOLLA, CA, April 02, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the closing of its previously announced public offering of an aggregate of 1,388,888 shares of its common stock (or common stock equivalents in lieu thereof), Series E-1 warrants to purchase up to 1,388,888 shares of common stock, short-term Series E-2 warrants to purchase up to 1,388,888 shares of common stock and short-term Series E-3 warrants to purchase up to 1,388,888 shares of common stock (all the warrants, collectively, the "Series Warrants"), at a combined public offering price of $3.60 per share (or per common stock equivalent in lieu thereof) and accompanying Series Warrants. The Series Warrants have an exercise price of $3.20 per share and are exercisable immediately upon issuance. The Series E-1 warrants expire on the five-year anniversary of the initial issuance date. The short-term Series E-2 warrants expire on the eighteen-month anniversary of the initial issuance date. The short-term Series E-3 warrants expire on the nine-month anniversary of the initial issuance date.
Neutral
Zacks Investment Research
2 months ago
GRI Stock Down on Public Offering Despite Encouraging IPF Study Data
GRI stock plunges on the pricing of its public offering, paring the gains witnessed following positive IPF study results.
Neutral
GlobeNewsWire
2 months ago
GRI Bio Announces Pricing of $5.0 Million Public Offering
LA JOLLA, CA, April 01, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the pricing of a public offering of an aggregate of 1,388,888 shares of its common stock (or common stock equivalents in lieu thereof), Series E-1 warrants to purchase up to 1,388,888 shares of common stock, short-term Series E-2 warrants to purchase up to 1,388,888 shares of common stock and short-term Series E-3 warrants to purchase up to 1,388,888 shares of common stock (all the warrants, collectively, the "Series Warrants"), at a combined public offering price of $3.60 per share (or per common stock equivalent in lieu thereof) and accompanying Series Warrants. The Series Warrants will have an exercise price of $3.20 per share and will be exercisable immediately upon issuance. The Series E-1 warrants will expire on the five-year anniversary of the initial issuance date. The short-term Series E-2 warrants will expire on the eighteen-month anniversary of the initial issuance date. The short-term Series E-3 warrants will expire on the nine-month anniversary of the initial issuance date. The closing of the offering is expected to occur on or about April 2, 2025, subject to the satisfaction of customary closing conditions.
Positive
Benzinga
2 months ago
Why Is Nano Cap GRI Bio Stock Skyrocketing On Tuesday?
GRI Bio, Inc. GRI stock is trading on Tuesday with a strong session volume of 6.9 million compared to an average volume of 17.35K, as per data from Benzinga Pro.
Charts implemented using Lightweight Charts™